Clinical Trials

57 enrolled

Prostatic Neoplasms

NCT03220022 2026-04-13

Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

46 enrolled 19 charts

Lymphoma, AIDS-Related

NCT04301076 2026-04-13

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)

Phase 1 Suspended

30 enrolled

Lymphoma, HTLV-I Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04577833 2026-04-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04662580 2026-04-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT05818683 2026-04-13

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

300 enrolled

Phase 1 Not yet recruiting

Metastatic Castration-resistant Prostate Neoplasms

NCT07444710 2026-04-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

16 enrolled

Ann Arbor Stage II Mantle Cell Lymphoma

NCT06421935 2026-03-24

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT03819296 2026-03-11

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer

800 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Colitis, Lung Neoplasms, Urogenital Neoplasms

NCT05157971 2026-03-05

Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia

24 enrolled

Burkitt Lymphoma

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

56 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04739813 2026-02-24

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

25 enrolled

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

12 enrolled

Prostatic Neoplasms

NCT02776436 2026-02-17

REDEX

46 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT04850495 2026-02-06

Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1 Suspended

38 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

174 enrolled

Lymphoma, B-Cell

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

247 enrolled 53 charts

Phase 1 Not yet recruiting

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT07278856 2025-12-12

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

20 enrolled

Lymphoma, T-Cell

NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

18 enrolled

Metastatic Hormone Refractory Prostate Cancer

NCT03595917 2025-11-04

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

LymphoidMyeloidOther hematologic neoplasm

40 enrolled

Burkitt Lymphoma, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT03816332 2025-10-09

Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers

12 enrolled 13 charts

Dermatologic

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT05270057 2025-10-09

LONCA

11 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell

NCT05276492 2025-10-03

Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.

50 enrolled

Prostatic Neoplasms

NCT04666129 2025-08-17

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

48 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

LymphoidOther solid neoplasm

480 enrolled

Advanced Solid Tumor

NCT06977711 2025-08-05

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

10 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03742258 2025-06-18

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

12 enrolled 13 charts

Lymphoma, Large B-Cell, Diffuse

NCT02913196 2025-05-23

Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC

16 enrolled

Prostate Cancer Metastatic

NCT01998971 2025-04-25

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

240 enrolled 3 FDA

Plasma cell

Multiple Myeloma

NCT06251180 2025-03-25

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

112 enrolled

Lymphoma, B-Cell

NCT03792256 2025-03-21

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

12 enrolled 24 charts

Leukemia, Lymphoid, Recurrence, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01792687 2025-03-04

Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate

6 enrolled

Prostatic Neoplasms

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

11 enrolled 16 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05295927 2025-02-03

A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)

3 enrolled

Prostatic Neoplasms

NCT03467373 2025-01-17

A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

111 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06566989 2024-10-23

MK-5684-008

8 enrolled

Prostatic Neoplasms

NCT04291664 2024-10-17

PK and Dose Escalation and Expansion Study of DST-2970

26 enrolled

Prostatic Neoplasms

NCT06554639 2024-10-15

MK-5684-011

12 enrolled

Prostatic Neoplasms

NCT05084859 2024-08-09

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT01523977 2024-07-18

CRAD001NUS175T

22 enrolled

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04790903 2024-07-11

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

50 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04933617 2024-07-09

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

8 enrolled 17 charts

Burkitt Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

52 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

NCT04677855 2024-04-10

Study of PCUR-101 in Combination With ADT in Patients With mCRPC

7 enrolled

Prostatic Neoplasms

NCT04083898 2024-03-19

Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

15 enrolled

Plasma cell

Multiple Myeloma

NCT04548700 2024-03-07

Liposomal Mitoxantrone Hydrochloride Injection,Cyclophosphamide, Vincristine and Prednisone in the Treatment of PTCL

38 enrolled